SK Chemical-developed hemophilia treatment applied for EMA approval
A hemophilia treatment, developed by the SK Chemicals’ own technology, is about to target the foreign advanced markets.
On the 23rd, SK Chemicals(CEO Man-hoon Park) announced CSL, a partnering company, completed the European Medicines Agency’s(EMA) commercialization approval application of ‘NBP6...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
